Ex-Cochlear boss Chris Roberts gets new role at OncoSil
Chris Roberts, the former head of biotech giant Cochlear, has taken on the chairman role at medical device company OncoSil.
Shares in the Australian-listed company jumped on the news, sitting 4.1 per cent higher, at 12.5c.
“I am excited to lead the board as OncoSil draws nearer to commercialising its innovative technology which has the potential to significantly improve the lives of people with cancer,” Dr Roberts said.
“There have been several rewarding developments in recent months with the progression of the global pancreatic study program and I look forward to extending my involvement in the company’s’ overall direction.”
Dr Roberts, who headed up Cochlear for more than 10 years before leaving the company in 2015, has been on the board of OncoSil since last January.
OncoSil is pushing ahead with European approval for its device, which provides radiation therapy to diseased cells through material implanted in the affected organ. The company, founded in 2013 to progress the technology to commercialisation, is focused on pancreatic and primary liver cancer, and the device is used in conjunction with chemotherapy.
“We are grateful for the contribution of Dr Roberts since he joined OncoSil as a non-executive director and are confident his expertise will continue to prove invaluable as he leads our board,” OncoSil chief executive Daniel Kenny said.
“Dr Roberts boasts a history of success in the development and commercialisation of medical technologies and his new appointment is very timely as we continue to advance toward commercialisation of a medical radiation treatment for pancreatic cancer and other solid tumours.”
OSL Price at posting:
12.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)